EU: "potential serious risk" definition for devices
This article was originally published in Clinica
Executive Summary
The European Commission's Directorate General Enterprise is to publish a list of examples of issues that would not normally be considered as grounds for a "potential serious risk to public health" in the context of Directive 2001/83/EC, the Community code relating to medicinal products for human use. The examples promise to be useful to manufacturers of combination products and products on the drug/device borderline area, as well as of general background use to all manufacturers of medtech products.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.